Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Journal of the American College of Cardiology·2024
Same author

The Term 'Deselect' is Ambiguous as Used in Research Studies to Support Prescription to Nonprescription Switches.

Therapeutic innovation & regulatory science·2023
Same author

Modeling the potential benefit of an over-the-counter progestin-only pill in preventing unintended pregnancies in the U.S.

Contraception·2022
Same author

Cerebrotendinous xanthomatosis-associated diarrhea and response to chenodeoxycholic acid treatment.

JIMD reports·2020
Same author

Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.

Annals of internal medicine·2019
Same author

Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

The New England journal of medicine·2019

Related Experiment Video

Updated: May 10, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Intermittent claudication: new targets for drug development.

Eric P Brass1

  • 1Department of Medicine, Center for Clinical Pharmacology, Harbor-UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA. ebrass@ucla.edu

Drugs
|June 19, 2013
PubMed
Summary
This summary is machine-generated.

Peripheral artery disease (PAD) causes leg pain and walking difficulty due to atherosclerosis. New drug therapies targeting muscle metabolism, oxidative stress, and blood flow are needed to improve exercise capacity and reduce disability in PAD patients.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Related Experiment Videos

Last Updated: May 10, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Area of Science:

  • Vascular Medicine
  • Pharmacology
  • Exercise Physiology

Background:

  • Peripheral artery disease (PAD) significantly increases cardiovascular morbidity and mortality.
  • PAD causes substantial disability through impaired walking ability, even in patients without classic claudication.
  • Current treatments for PAD focus on risk reduction and exercise enhancement, but limitations exist, highlighting the need for novel pharmacotherapies.

Purpose of the Study:

  • To explore multifactorial contributors to exercise impairment in PAD.
  • To identify potential targets for new drug therapies to improve physical function in PAD.
  • To review emerging strategies for pharmacologic revascularization, skeletal muscle metabolism enhancement, oxidative stress reduction, and atherosclerotic lesion regression.

Main Methods:

  • Review of current understanding of PAD pathophysiology and its impact on skeletal muscle.
  • Analysis of potential therapeutic targets including angiogenesis, muscle metabolism, oxidative stress, and atherosclerosis.
  • Exploration of pharmacologic approaches to improve blood flow, muscle mass, and exercise performance.

Main Results:

  • PAD pathophysiology involves complex changes in skeletal muscle distal to arterial stenoses.
  • Potential therapeutic targets include enhancing angiogenesis, improving skeletal muscle metabolism, reducing oxidative stress, and inducing atherosclerotic lesion regression.
  • Novel drug therapies could target microcirculation, increase muscle mass, or mimic preconditioning adaptations to improve physical performance.

Conclusions:

  • The multifactorial nature of PAD-related exercise impairment necessitates diverse therapeutic strategies.
  • Advances in understanding PAD pathophysiology offer promising targets for new pharmacotherapies.
  • Effective translation of these targets into therapeutics is crucial, given the increasing prevalence of PAD.